View source for Mesothelioma Prognostic Factors

{{#seo:
|title=Mesothelioma Prognostic Factors (2026): 5 Variables, 18.1-Month NIVO+IPI Survival
|title_mode=replace
|description=The 5 prognostic factors that drive mesothelioma survival in 2026: ECOG performance status, histology, stage, age/sex, treatment access. Evidence-based.
|keywords=mesothelioma prognostic factors, ECOG performance status mesothelioma, mesothelioma survival predictors, PLECH score, CALGB EORTC mesothelioma, mesothelioma histology prognosis
|author=Danziger & De Llano Editorial Team
|published_time=2026-05-25
|type=Article
|image=logo.png
|image_alt=WikiMesothelioma — Mesothelioma Prognostic Factors
}}

Mesothelioma prognostic factors are the clinical, pathological, and laboratory variables that predict how long a patient with mesothelioma is likely to survive and which treatments they can safely access. Across multiple peer-reviewed studies, the five most consistently validated prognostic factors are '''disease stage''' at diagnosis, '''histological subtype''' (epithelioid, biphasic, or sarcomatoid), '''Eastern Cooperative Oncology Group performance status (ECOG PS)''', '''age and sex''', and '''access to multimodal treatment'''. Modern composite scoring systems — including the EORTC score, the CALGB score, and the newer PLECH score (2025) — integrate these variables into clinically actionable risk strata.<ref name="nakajima_fda_2022" /><ref name="ecog_crs_hipec_2021" /><ref name="danish_guidelines_2025" /><ref name="plech_2025" />

{| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
|-
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | Mesothelioma Prognostic Factors
|-
| colspan="2" style="padding:10px; text-align:center; font-style:italic; border-bottom:1px solid #dee2e6;" | The Five Variables That Predict Survival
|-
| style="padding:10px; font-weight:bold; width:48%; border-bottom:1px solid #dee2e6;" | 5-Year Relative Survival (All Stages)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | ~12% (NCI SEER, 2026)
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Median Overall Survival (OS), NIVO+IPI
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 18.1 months
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Median OS, Platinum-Pemetrexed
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 14.1 months
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | 3-Year OS, NIVO+IPI
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 23%
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | ECOG PS 0–1 vs PS ≥2 (ICI mOS)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 12.6 vs 3.1 months
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Non-Epithelioid mOS, NIVO+IPI vs Chemo
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 16.9 vs 8.8 months
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Peritoneal MPM CRS+HIPEC 3-Year SR vs CRS+IP Chemo
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 65% vs 33%
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | BAP1 Germline Carrier Median OS
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 5+ years
|-
| style="padding:10px; font-weight:bold;" | Best-Performing Score (2026)
| style="padding:10px;" | PLECH (Area Under the Curve, or AUC, 0.70)
|}

While prognostic factors do not determine outcomes individually — survival is the result of how they combine with treatment access, supportive care, and time of diagnosis — they remain the framework physicians use to decide treatment intent, trial eligibility, and surgical candidacy. Patients with epithelioid histology, early-stage disease, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1 are offered curative-intent multimodal protocols, while patients with sarcomatoid histology, advanced stage, and ECOG PS ≥3 are offered palliative care.

The cost-facts table below reflects current 2026 U.S. averages from public and industry sources and is positioned here so readers can cross-check the page's economic claims against the table on each visit. Costs are billed amounts and vary by insurance, region, and center.

{| class="wikitable" style="width:100%;"
|-
! style="width:35%;" | Cost / Compensation Dimension !! Typical 2026 Range (USD) !! Verified
|-
| First-year total billed cost of mesothelioma treatment || $80,000–$160,000 || 2026-05-25
|-
| FDA-approved immunotherapy regimen (nivolumab + ipilimumab, or NIVO+IPI), annual || $180,000+ || 2026-05-25
|-
| Pleurectomy/decortication (P/D) procedural cost || $55,000–$95,000 || 2026-05-25
|-
| Standard cisplatin/pemetrexed chemotherapy course (6 cycles) || $20,000–$50,000 || 2026-05-25
|-
| Average U.S. mesothelioma legal settlement || $1.0M–$1.4M || 2026-05-25
|}

== Executive Summary ==

Mesothelioma prognosis is determined not by any single variable but by the interaction of five validated factors. '''Disease stage''' captures how far the cancer has spread; '''histology''' captures how the tumor cells look and behave; '''ECOG performance status''' captures whether the patient is well enough to tolerate aggressive treatment; '''age and sex''' modify both biology and treatment access; and '''treatment center experience''' modifies whether the patient receives state-of-the-art multimodal care. In 2026, the first-line immunotherapy regimen nivolumab + ipilimumab (NIVO+IPI) — FDA-approved for unresectable malignant pleural mesothelioma (MPM) — extends median overall survival (OS) to 18.1 months from the 14.1 months historically achieved with platinum-pemetrexed chemotherapy, but only for patients with ECOG PS 0 or 1.<ref name="nakajima_fda_2022" /> Patients with ECOG PS ≥2 are largely excluded from these regimens and experience markedly shorter survival — median 3.1 months versus 12.6 months in pooled immune checkpoint inhibitor (ICI) cohorts.<ref name="ecog_ici_oncol_pract_2022" /> Across all stages of pleural mesothelioma, the 5-year relative survival rate is approximately 12%; for peritoneal mesothelioma treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in eligible patients, peer-reviewed cohort data show a 3-year survival rate of approximately 65%, compared with 33% in CRS-plus-postoperative-intraperitoneal-chemotherapy comparators.<ref name="seer_2026" /><ref name="ecog_crs_hipec_2021" />

== At a Glance ==

* '''Five validated prognostic factors''' drive mesothelioma survival: stage, histology, ECOG performance status, age/sex, and treatment access.
* '''ECOG PS is the single most universally applied prognostic and treatment-eligibility variable''' — it gates access to immunotherapy, multimodal surgery, and most clinical trials.<ref name="danish_guidelines_2025" />
* '''Epithelioid histology has the best prognosis''' (~60% of pleural cases; longer overall survival, or OS); '''sarcomatoid has the worst''' (~10% of cases; weakest chemotherapy response).<ref name="danish_guidelines_2025" />
* '''Non-epithelioid patients derive the largest relative benefit from NIVO+IPI''' (hazard ratio, or HR, 0.46) because chemotherapy performs especially poorly in sarcomatoid disease.<ref name="nakajima_fda_2022" />
* '''ECOG performance status is an independent risk factor''' for survival in peritoneal mesothelioma on multivariate analysis (p=0.017).<ref name="ecog_crs_hipec_2021" />
* '''The PLECH score (2025)''' — combining platelet count, lactate dehydrogenase (LDH), ECOG PS, chest pain, and histology — outperforms the older EORTC and CALGB scores (AUC 0.70 vs 0.57 and 0.60).<ref name="plech_2025" />
* '''Female patients consistently show better survival''' than male patients across mesothelioma cohorts, after adjustment for stage and histology.<ref name="danish_guidelines_2025" />
* '''Approximately 90+ active clinical trials''' are enrolling mesothelioma patients as of early 2026, with most requiring ECOG PS 0–1.<ref name="clinical_trials_landscape_2026" />

== Key Facts ==

{| class="wikitable" style="width:100%;"
|-
! style="width:42%;" | Metric !! Value !! Source / Notes
|-
| 5-year relative survival, all stages combined || ~12% || NCI Surveillance, Epidemiology, and End Results (SEER), 2026<ref name="seer_2026" />
|-
| 3-year survival rate, peritoneal mesothelioma (CRS+HIPEC eligible vs CRS+IP chemo comparator) || ~65% vs ~33% || PMID 34650746 (44-patient retrospective cohort)<ref name="ecog_crs_hipec_2021" />
|-
| Median OS, NIVO+IPI (CheckMate 743) || 18.1 months || U.S. Food and Drug Administration (FDA) BLA review; PMID 34462287<ref name="nakajima_fda_2022" />
|-
| Median OS, platinum-pemetrexed (CheckMate 743) || 14.1 months || FDA BLA review; PMID 34462287<ref name="nakajima_fda_2022" />
|-
| Hazard ratio for OS, NIVO+IPI vs chemotherapy || 0.74 (95% CI, 0.61–0.89; p=0.002) || CheckMate 743<ref name="nakajima_fda_2022" />
|-
| 3-year OS rate, NIVO+IPI vs chemotherapy || 23% vs 15% || CheckMate 743 3-year update
|-
| Non-epithelioid mOS, NIVO+IPI vs chemotherapy || 16.9 vs 8.8 months (HR 0.46; 95% CI 0.31–0.70) || CheckMate 743<ref name="nakajima_fda_2022" />
|-
| Epithelioid mOS, NIVO+IPI vs chemotherapy || 18.7 vs 16.2 months (HR 0.85; 95% CI 0.68–1.06) || CheckMate 743<ref name="nakajima_fda_2022" />
|-
| ECOG PS as independent prognostic factor in peritoneal mesothelioma (multivariate analysis) || Confirmed (p=0.017) || PMID 34650746<ref name="ecog_crs_hipec_2021" />
|-
| Median OS, ICI patients with ECOG PS 0–1 (all advanced solid tumors) || 12.6 months || JCO Oncology Practice 2022<ref name="ecog_ici_oncol_pract_2022" />
|-
| Median OS, ICI patients with ECOG PS ≥2 (all advanced solid tumors) || 3.1 months || JCO Oncology Practice 2022<ref name="ecog_ici_oncol_pract_2022" />
|-
| PLECH score area under the curve (AUC) for 1-year OS prediction || 0.70 || PLECH Karger Oncology, 2025<ref name="plech_2025" />
|-
| CALGB score AUC for 1-year OS prediction || 0.60 || PLECH Karger Oncology, 2025<ref name="plech_2025" />
|-
| EORTC score AUC for 1-year OS prediction || 0.57 || PLECH Karger Oncology, 2025<ref name="plech_2025" />
|-
| Average annual U.S. mesothelioma incidence || ~3,000 cases || NCI / American Cancer Society
|-
| Active recruiting mesothelioma clinical trials (early 2026) || ~90–93 || ClinicalTrials.gov<ref name="clinical_trials_landscape_2026" />
|}

== What Are the Most Important Prognostic Factors in Mesothelioma? ==

Multiple peer-reviewed studies, including the comprehensive Danish clinical guidelines published in 2025, identify five core prognostic factors that together predict survival and gate treatment access.<ref name="danish_guidelines_2025" /> The factors are described in detail below.

=== Factor 1: Disease Stage ===

Disease stage at diagnosis remains a fundamental survival predictor. The American Joint Committee on Cancer (AJCC) 8th Edition Tumor, Node, Metastasis (TNM) staging system is the current standard for pleural mesothelioma. In the pivotal CheckMate 743 trial, 87% of patients in the immunotherapy arm presented with Stage III or Stage IV disease — reflecting how typical the late-stage presentation of malignant pleural mesothelioma (MPM) is at diagnosis.<ref name="nakajima_fda_2022" /> In peritoneal mesothelioma specifically, TNM stage was confirmed as an independent risk factor for prognosis in multivariate Cox regression analysis (OR 2.142; p=0.038), alongside ECOG score and treatment modality.<ref name="ecog_crs_hipec_2021" />

Population-level data from the NCI Surveillance, Epidemiology, and End Results (SEER) program show that the 5-year relative survival rate across all stages combined is approximately 12% — an improvement from the 5–8% seen in the early 2000s, but still representing a disease with a very poor prognosis.<ref name="seer_2026" /> In contrast, peritoneal mesothelioma treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in eligible patients achieves substantially better near-term survival than CRS-alone comparators — peer-reviewed cohort data report a 3-year survival rate of approximately 65% in the CRS+HIPEC subgroup versus 33% in CRS plus postoperative intraperitoneal chemotherapy. This difference reflects both disease biology (peritoneal disease tends to remain locally aggressive rather than metastasizing widely) and the intensity of the surgical approach.<ref name="ecog_crs_hipec_2021" />

The clinical implication is that stage informs treatment intent. Stage I and Stage II patients with epithelioid histology and ECOG PS 0–1 may be candidates for curative-intent multimodal surgery; Stage III patients are candidates for chemoimmunotherapy with selective surgery; Stage IV patients are typically managed with systemic therapy and palliative care.<ref name="danish_guidelines_2025" />

=== Factor 2: Histological Subtype ===

Histological subtype is one of the strongest prognostic determinants in malignant pleural mesothelioma.<ref name="danish_guidelines_2025" /> The three principal subtypes are epithelioid, sarcomatoid, and biphasic.

* '''Epithelioid mesothelioma''' is the most common subtype, accounting for approximately 60% of pleural cases (76% in the CheckMate 743 cohort). It carries the best prognosis, the most reliable response to chemotherapy, and the longest overall survival across treatment regimens.<ref name="nakajima_fda_2022" />
* '''Sarcomatoid mesothelioma''' accounts for approximately 10% of cases and carries the worst prognosis, with the poorest response to chemotherapy. However, sarcomatoid tumors often express higher levels of programmed death-ligand 1 (PD-L1), which may make them more responsive to immunotherapy than to chemotherapy alone.<ref name="nakajima_fda_2022" />
* '''Biphasic mesothelioma''' accounts for approximately 25–30% of cases and shows an intermediate prognosis. The outcome worsens as the sarcomatoid component increases. Many surgical multimodal protocols restrict candidacy to biphasic tumors with less than 50% sarcomatoid component.<ref name="danish_guidelines_2025" />

The clinical impact of histology is most clearly illustrated in CheckMate 743 subgroup data, where non-epithelioid patients derived a substantially greater relative benefit from nivolumab + ipilimumab (NIVO+IPI) compared with chemotherapy than epithelioid patients did. The non-epithelioid hazard ratio (HR) for overall survival was 0.46 (95% CI, 0.31–0.70), compared with 0.85 (95% CI, 0.68–1.06) for the epithelioid subgroup. The reason is largely that chemotherapy performs especially poorly in sarcomatoid disease, leaving more headroom for immunotherapy to outperform it.<ref name="nakajima_fda_2022" />

According to multiple sources, female sex distribution differs by subtype and primary site: biphasic and sarcomatoid pleural mesothelioma show stronger male predominance, while peritoneal mesothelioma — disproportionately epithelioid — shows a near-equal male-to-female ratio.<ref name="danish_guidelines_2025" />

=== Factor 3: ECOG Performance Status ===

Eastern Cooperative Oncology Group performance status (ECOG PS) is a clinician-assessed score measuring a cancer patient's ability to perform everyday activities. It is the most universally applied performance-status measure in oncology and is used for:

* Determining eligibility for chemotherapy, immunotherapy, and clinical trials
* Guiding dose-intensity decisions
* Estimating prognosis

The ECOG scale and its treatment implications are summarized below.

{| class="wikitable" style="width:100%;"
|-
! style="width:8%;" | Score !! style="width:32%;" | Definition !! style="width:30%;" | Clinical Interpretation !! Treatment Implications
|-
| 0 || Fully active; no restrictions || Excellent performance status; able to perform all pre-disease activities || Eligible for all treatment modalities including aggressive multi-agent chemotherapy, major surgery, immunotherapy, and all Phase III trials
|-
| 1 || Restricted in strenuous physical activity but ambulatory; able to do light work || Mild symptoms, still functional || Eligible for essentially all standard systemic therapies and most clinical trials
|-
| 2 || Ambulatory and capable of self-care; unable to work; up and about more than 50% of waking hours || Moderate symptoms; intermediate group || Increasingly included in trials; requires heightened toxicity monitoring; some mesothelioma-specific trials exclude this group
|-
| 3 || Capable of only limited self-care; confined to bed or chair more than 50% of waking hours || Poor prognosis; limited functional reserve || Palliative care focus; systemic chemotherapy generally contraindicated; aggressive treatment delays end-of-life care without benefit
|-
| 4 || Completely disabled; cannot carry on any self-care; totally confined to bed || Very poor prognosis || Systemic therapy rarely appropriate; exclusively palliative and supportive care
|-
| 5 || Deceased || — || —
|}

In mesothelioma specifically, the pivotal CheckMate 743 trial — which established nivolumab + ipilimumab as the first new FDA-approved first-line regimen in over 15 years — restricted enrollment to patients with ECOG PS 0 or 1. Of the immunotherapy arm, 38% had ECOG PS 0 and 62% had ECOG PS 1; ECOG PS ≥2 patients were almost entirely excluded.<ref name="nakajima_fda_2022" />

The survival impact of ECOG performance status outside the trial population is substantial. A retrospective analysis of 257 patients with advanced solid tumors treated with immune checkpoint inhibitors (ICIs) found a median overall survival of 12.6 months for ECOG PS 0–1 versus 3.1 months for ECOG PS ≥2 (p<0.001). The overall response rate was 23% for PS 0–1 versus 8% for poor PS (p=0.005).<ref name="ecog_ici_oncol_pract_2022" />

In peritoneal mesothelioma, ECOG performance status is an independent prognostic factor confirmed in multivariate Cox regression. A retrospective analysis of 44 peritoneal mesothelioma patients treated with cytoreductive surgery (CRS) found that the cytoreductive-surgery-plus-HIPEC subgroup achieved a 3-year survival rate of 65.22% versus 33.33% for the cytoreductive-surgery-plus-postoperative-intraperitoneal-chemotherapy comparator. On multivariate analysis, ECOG score was independently associated with prognosis (p=0.017), alongside TNM stage and treatment modality.<ref name="ecog_crs_hipec_2021" />

Patients with ECOG PS ≥3 should generally not receive systemic chemotherapy because the toxicity profile delays end-of-life care without demonstrable survival benefit. This is a clinical consensus across the Danish clinical guidelines and prior treatment-eligibility frameworks.<ref name="danish_guidelines_2025" />

=== Factor 4: Age and Sex ===

Age and sex are both prognostic modifiers in mesothelioma, though they operate differently from the other factors. Mean age at diagnosis exceeds 70 years in most Western countries because of mesothelioma's long latency (approximately 40 years between asbestos exposure and disease onset).<ref name="nakajima_fda_2022" /> Older age is associated with worse outcomes in part because of comorbidity burden and in part because surgical multimodal protocols are restricted to patients under approximately 75 years.<ref name="danish_guidelines_2025" />

According to multiple registry and case-series analyses, female patients show better overall survival than male patients across mesothelioma cohorts, after adjustment for stage and histology. The male-to-female ratio for pleural mesothelioma is approximately 3.5–4:1 in most U.S. series, reflecting historical occupational exposure patterns; for peritoneal mesothelioma, the male-to-female ratio is closer to 1.2:1.<ref name="danish_guidelines_2025" /> Several registry analyses describe meaningfully better survival in women than in men with mesothelioma; the underlying mechanism is debated and may involve hormonal modulation, immune-response differences, or differences in exposure intensity rather than a single causal pathway.<ref name="seer_2026" />

For women in particular, mesothelioma is increasingly attributed to environmental, para-occupational (take-home), or unknown exposure pathways rather than direct workplace exposure. This shifts both the clinical profile (younger age at diagnosis is more common in para-occupational cases) and the legal profile (different defendants, different proof requirements) of female mesothelioma cases. See [[Secondary_Asbestos_Exposure]] for the detailed exposure-pathway analysis.

Germline mutations in BAP1 (BRCA-Associated Protein 1) are a special case: BAP1 carriers tend to present younger, often with multifocal low-grade tumors, and carry a median overall survival exceeding 5 years — substantially longer than non-carriers.<ref name="danish_guidelines_2025" />

=== Factor 5: Treatment Access and Volume ===

Whether a patient with mesothelioma is treated at a high-volume academic center with multidisciplinary expertise is itself a prognostic factor. The Danish clinical guidelines and multiple registry analyses describe surgery within multimodal protocols as restricted to patients treated at centers with thoracic surgical expertise and pathology infrastructure capable of biphasic-component grading, which is itself a function of center volume.<ref name="danish_guidelines_2025" /> Across registry comparisons, peritoneal mesothelioma patients tend to be diagnosed younger (median ~62 years vs ~73 years for pleural), are more often treated at academic centers, and more often undergo surgery (CRS+HIPEC), which together explain a meaningful share of the median-OS gap between peritoneal and pleural disease.<ref name="ecog_crs_hipec_2021" />

Treatment access has direct implications for the choice of first-line regimen, surgical candidacy, and clinical trial enrollment. Where insurance coverage, trust-fund eligibility, and Veterans Affairs benefits intersect with the prognostic timeline, the financial planning has to track the medical plan rather than compete with it. See the Compensation section below for the legal-resource pathways patients commonly pursue.

== What Molecular Biomarkers Affect Mesothelioma Prognosis? ==

Beyond the five clinical prognostic factors above, several molecular markers influence prognosis. These are not used as standalone prognostic tools but are integrated into pathology reports and trial-enrollment decisions.

* '''BAP1 (BRCA-Associated Protein 1) loss''' — immunohistochemistry (IHC)-detected loss of nuclear BAP1 expression is associated with a more favorable prognosis, particularly in younger patients with germline BAP1 mutations. Germline BAP1 mutations are found in approximately 7–12% of patients with pleural mesothelioma; carriers tend to develop the disease at younger ages and survive longer than non-carriers.<ref name="danish_guidelines_2025" />
* '''CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A) deletion''' — homozygous deletion of CDKN2A, detected by fluorescence in situ hybridization (FISH), or its surrogate methylthioadenosine phosphorylase (MTAP) loss, detected by IHC, correlates with shorter overall survival. CDKN2A deletion is found in 40–70% of epithelioid and biphasic pleural mesothelioma and approximately 90% of sarcomatoid disease.<ref name="danish_guidelines_2025" />
* '''Programmed death-ligand 1 (PD-L1) expression''' — higher PD-L1 expression correlates with worse survival in chemotherapy-treated patients but may predict immunotherapy benefit. Exploratory subgroup analyses in CheckMate 743 suggested a larger OS benefit from NIVO+IPI in PD-L1 ≥1% tumors.<ref name="nakajima_fda_2022" />
* '''NF2 / Merlin loss''' — deletions or mutations of the NF2 gene are common in pleural mesothelioma but are not currently used as routine prognostic biomarkers because of late and heterogeneous occurrence.<ref name="danish_guidelines_2025" />

Several clinical and laboratory variables described in the Danish clinical guidelines are also recognized as prognostic in mesothelioma: chest pain at diagnosis, weight loss, dyspnea, anemia, leukocytosis, thrombocytosis, elevated lactate dehydrogenase (LDH), and elevated platelet count.<ref name="danish_guidelines_2025" /><ref name="plech_2025" />

== Which Prognostic Scoring Systems Are Used in Mesothelioma? ==

Several composite prognostic scoring systems integrate the individual variables above into clinically actionable risk strata. Their performance has been compared head-to-head in retrospective cohorts. The 2025 PLECH score is the newest and best-performing system in published comparisons.<ref name="plech_2025" />

{| class="wikitable" style="width:100%;"
|-
! style="width:14%;" | Score !! style="width:36%;" | Key Variables !! style="width:18%;" | AUC for 1-Year OS !! ECOG Included? !! Status
|-
| EORTC || Performance status (PS), histology, white blood cell (WBC) count, sex, type of diagnosis || ~0.57<ref name="plech_2025" /> || Yes (PS) || Historical; recent cohorts show inconsistent prediction
|-
| CALGB || Age, PS, lactate dehydrogenase (LDH), WBC, hemoglobin (Hgb), histology || ~0.60<ref name="plech_2025" /> || Yes (PS) || Historical; the most widely referenced score for predicting chemotherapy benefit
|-
| Brims || Decision tree across multiple clinical variables || Significant OS prediction (p<0.01) || Yes || UK-derived; better performance in head-to-head comparisons with EORTC and CALGB
|-
| modified Glasgow Prognostic Score (mGPS) || C-reactive protein (CRP) and albumin || Significant OS prediction (p=0.01) || No || Inflammation-based; simple lab-only score
|-
| LENT || LDH, ECOG PS, neutrophil-to-lymphocyte ratio (NLR), tumor type || Inconsistent validation across cohorts || Yes || Originally validated in malignant pleural effusion, not exclusively mesothelioma
|-
| PLECH (2025) || Platelets, LDH, ECOG ≥2, chest pain, histology || 0.70<ref name="plech_2025" /> || Yes || Newest; derived from 262 patients at two Mexican centers; outperforms EORTC and CALGB
|}

The PLECH score is a 0–7 point system in which elevated platelet count contributes +2 points, elevated LDH +1, ECOG ≥2 +1, chest pain at diagnosis +2, and non-epithelioid histology +1. A high score (≥3) was associated with worse overall survival (12.3 vs 20.1 months; p<0.001) and worse progression-free survival (6.4 vs 11.3 months; p<0.001) in the derivation cohort.<ref name="plech_2025" />

== Compensation, Trust Funds, and the Prognostic Timeline ==

The prognostic profile a patient receives at diagnosis directly shapes how compensation planning unfolds. A patient with ECOG PS 0–1 and epithelioid Stage I–II disease has the longest planning horizon: years of treatment decisions, trial considerations, and financial planning. A patient with ECOG PS 2–3 and non-epithelioid Stage IV disease has a substantially compressed horizon — often months — and the legal and financial timeline has to match.

Asbestos trust funds — established under Section 524(g) of the U.S. Bankruptcy Code — currently hold an aggregate of approximately $30 billion to compensate mesothelioma patients exposed to defendants who have since filed for bankruptcy. The timing of trust-fund filings against the prognostic timeline is one of the most consequential decisions a patient and family make in the first 30 days after diagnosis.

=== Settlements and Verdicts ===

Average mesothelioma legal settlements range from $1.0 million to $1.4 million, with average jury verdicts in the $5 million to $11.4 million range. Plaintiff law firms with experience in compressed-timeline mesothelioma cases structure compensation pathways to align trust-fund filings, settlement negotiations, and active treatment so that financial planning supports rather than competes with the medical plan. See [[#External Links|External Links]] for resources.

== Treatment Access by Prognostic Profile ==

The treatment options realistically available to a mesothelioma patient are a function of the prognostic profile they present with. The table below summarizes typical treatment access by ECOG score, the single variable most commonly used to determine eligibility.

{| class="wikitable" style="width:100%;"
|-
! style="width:10%;" | ECOG Score !! Treatment Options Realistically Available !! Evidence
|-
| 0 || Full multimodal: lung-preserving surgery (pleurectomy/decortication or P/D), immunotherapy (NIVO+IPI), platinum-pemetrexed chemotherapy, clinical trials, cytoreductive surgery (CRS) + HIPEC for peritoneal disease || Best outcomes; 3-year OS up to 23% with NIVO+IPI; eligible for all modalities<ref name="nakajima_fda_2022" />
|-
| 1 || Full multimodal (same as ECOG 0) || Eligible for standard and experimental protocols; 62% of CheckMate 743 NIVO+IPI arm<ref name="nakajima_fda_2022" />
|-
| 2 || Limited systemic therapy (carboplatin+pemetrexed often preferred over cisplatin); selected trials; immunotherapy with heightened caution || Median OS ~3.1 months in pooled ICI cohorts vs 12.6 months for PS 0–1; largely excluded from mesothelioma-specific pivotal trials<ref name="ecog_ici_oncol_pract_2022" />
|-
| 3 || Palliative: best supportive care, symptom management, pleurodesis or indwelling pleural catheter (IPC) for effusion, palliative radiotherapy (RT) || Systemic chemotherapy generally contraindicated; delays end-of-life care without survival benefit<ref name="ecog_crs_hipec_2021" />
|-
| 4 || Exclusively palliative and supportive care || Systemic therapy rarely if ever appropriate<ref name="danish_guidelines_2025" />
|}

Approximately 90 to 93 mesothelioma clinical trials are actively recruiting as of early 2026. Most require ECOG PS 0–1 enrollment; a smaller number extend to ECOG PS 2 in specific protocols.<ref name="clinical_trials_landscape_2026" />

== Related WikiMesothelioma Resources ==

Patients and families researching mesothelioma prognosis often need to cross-reference related medical and legal topics. Helpful WikiMesothelioma pages include:

* [[Mesothelioma_Prognosis]] — broader prognostic context including survival statistics, life-expectancy ranges, and treatment-era comparisons
* [[Pleural_Mesothelioma]] — the most common mesothelioma type (~80–85% of cases), with detailed clinical and pathological coverage
* [[Peritoneal_Mesothelioma]] — abdominal mesothelioma, including CRS+HIPEC outcomes that drive the favorable 5-year survival in eligible patients
* [[Mesothelioma_Staging]] — AJCC 8th Edition TNM staging system in detail
* [[Mesothelioma_Treatment]] — first-line and second-line treatment regimens, including the NIVO+IPI immunotherapy backbone
* [[Asbestos_Trust_Funds]] — Section 524(g) trust-fund overview and filing pathways
* [[Mesothelioma_Specialists]] — high-volume mesothelioma treatment centers

== Frequently Asked Questions ==

=== What are the five most important prognostic factors in mesothelioma? ===

The five validated prognostic factors are: '''disease stage''' at diagnosis (AJCC 8th Edition TNM), '''histological subtype''' (epithelioid, biphasic, or sarcomatoid), '''ECOG performance status''' (0–4 scale), '''age and sex''' (older age and male sex correlate with worse outcomes), and '''treatment access''' (high-volume academic centers produce substantially better 5-year survival). ECOG performance status is the single most universally applied because it gates eligibility for immunotherapy, surgery, and most clinical trials.<ref name="danish_guidelines_2025" /><ref name="nakajima_fda_2022" />

=== How does ECOG performance status affect mesothelioma survival? ===

ECOG performance status has both direct and indirect effects on survival. Directly, in pooled cohorts of patients treated with immune checkpoint inhibitors, ECOG PS 0–1 patients had a median overall survival of 12.6 months versus 3.1 months for ECOG PS ≥2.<ref name="ecog_ici_oncol_pract_2022" /> Indirectly, ECOG PS gates access to the most effective therapies — the FDA-approved NIVO+IPI regimen, multimodal surgery, and most Phase III trials all require ECOG PS 0–1. Patients with ECOG PS ≥3 are typically managed with palliative care because systemic chemotherapy delays end-of-life care without demonstrable survival benefit.<ref name="ecog_crs_hipec_2021" />

=== Which histological subtype of mesothelioma has the best prognosis? ===

Epithelioid mesothelioma has the best prognosis. It accounts for approximately 60% of pleural mesothelioma cases and shows the most reliable chemotherapy response and the longest overall survival. Sarcomatoid mesothelioma — approximately 10% of cases — has the worst prognosis. Biphasic mesothelioma — approximately 25–30% of cases — has an intermediate prognosis that worsens as the sarcomatoid component increases.<ref name="danish_guidelines_2025" /><ref name="nakajima_fda_2022" />

=== What is the median survival for mesothelioma with the FDA-approved immunotherapy? ===

In the CheckMate 743 trial, patients with unresectable malignant pleural mesothelioma treated with first-line nivolumab + ipilimumab (NIVO+IPI) had a median overall survival of 18.1 months, compared with 14.1 months for patients treated with platinum-pemetrexed chemotherapy. The hazard ratio for overall survival was 0.74 (95% CI, 0.61–0.89; p=0.002). At 3-year follow-up, the OS rate was 23% in the NIVO+IPI arm versus 15% in the chemotherapy arm. ECOG PS 0–1 was a strict enrollment requirement.<ref name="nakajima_fda_2022" />

=== Why do peritoneal mesothelioma patients have better 5-year survival than pleural patients? ===

The near-term survival difference between peritoneal and pleural mesothelioma reflects three factors. First, peritoneal mesothelioma is more often locally aggressive and less often metastatic at diagnosis, making cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) viable for a higher proportion of patients. Second, peritoneal patients tend to be diagnosed younger (median ~62 years vs ~73 years for pleural). Third, peritoneal patients are more often treated at high-volume academic centers and more often receive surgery. In CRS+HIPEC-eligible peritoneal patients, peer-reviewed cohort data report a 3-year survival rate of approximately 65%, compared with 33% in CRS-plus-postoperative-intraperitoneal-chemotherapy comparators.<ref name="ecog_crs_hipec_2021" />

=== What is the PLECH score, and how does it compare to CALGB and EORTC? ===

The PLECH score is a 0–7 point composite prognostic score derived in 2025 from 262 patients at two Mexican cancer centers. It integrates five variables: elevated '''P'''latelet count (+2 points), elevated '''L'''DH (+1), '''E'''COG ≥2 (+1), '''C'''hest pain at diagnosis (+2), and non-epithelioid '''H'''istology (+1). A high score (≥3) was associated with worse overall survival (12.3 vs 20.1 months; p<0.001). In head-to-head comparison, PLECH had an area under the curve (AUC) of 0.70 for 1-year overall survival prediction, outperforming both CALGB (0.60) and EORTC (0.57).<ref name="plech_2025" />

== External Links ==

* [https://www.dandell.com/ Danziger & De Llano]
* [https://seer.cancer.gov/statfacts/html/meso.html NCI SEER — Mesothelioma Cancer Stat Facts]
* [https://clinicaltrials.gov/search?cond=mesothelioma ClinicalTrials.gov — Mesothelioma trial search]
* [https://www.cancer.gov/types/mesothelioma National Cancer Institute — Mesothelioma]

== References ==

<references>

<ref name="seer_2026">National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. Mesothelioma — Cancer Stat Facts. National Cancer Institute. 2026. Available at: [https://seer.cancer.gov/statfacts/ https://seer.cancer.gov/statfacts/]</ref>

<ref name="nakajima_fda_2022">Nakajima EC, Vellanki PJ, Larkins E, et al. FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma. ''Clin Cancer Res''. 2022;28(3):446–451. PMID: 34462287. Available at: [https://pubmed.ncbi.nlm.nih.gov/34462287/ https://pubmed.ncbi.nlm.nih.gov/34462287/]</ref>

<ref name="ecog_crs_hipec_2021">Wang T, Li H, Ye B, Zhang D. Value of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy to treat malignant peritoneal mesothelioma. ''Am J Transl Res''. 2021;13(9):10712–10720. PMID: 34650746. Available at: [https://pubmed.ncbi.nlm.nih.gov/34650746/ https://pubmed.ncbi.nlm.nih.gov/34650746/]</ref>

<ref name="danish_guidelines_2025">Panou V, Sørensen JB, Ravn J, Santoni-Rugiu E. Advances in diagnosis and management of pleural mesothelioma: the Danish clinical guidelines. ''Eur Clin Respir J''. 2025;12(1):2580795. PMID: 41179988. Available at: [https://pubmed.ncbi.nlm.nih.gov/41179988/ https://pubmed.ncbi.nlm.nih.gov/41179988/]</ref>

<ref name="ecog_ici_oncol_pract_2022">Krishnan M, Kasinath P, High R, Yu F, Teply BA. Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors. ''JCO Oncol Pract''. 2022;18(1):e175–e182. PMID: 34351819. Available at: [https://pubmed.ncbi.nlm.nih.gov/34351819/ https://pubmed.ncbi.nlm.nih.gov/34351819/]</ref>

<ref name="plech_2025">Guijosa A, Cabrera-Miranda LA, Gómez-García AP, Trejo Rosales R, Muñoz-Montaño W, Flores D, Reynoso-Noverón N, Arrieta O. Prognostic Factors in Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: Establishing the PLECH Baseline Risk Score. ''Oncology''. 2025. PMID: 40068665. Available at: [https://pubmed.ncbi.nlm.nih.gov/40068665/ https://pubmed.ncbi.nlm.nih.gov/40068665/]</ref>

<ref name="clinical_trials_landscape_2026">ClinicalTrials.gov Mesothelioma Trial Landscape. U.S. National Library of Medicine. Accessed 2026-01. Available at: [https://clinicaltrials.gov/search?cond=mesothelioma&aggFilters=status:rec https://clinicaltrials.gov/search?cond=mesothelioma]</ref>

</references>

[[Category:Medical]]
[[Category:Prognosis]]
[[Category:Mesothelioma]]